ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Recent FDA-Approved Medical Drugs or Medical Drug Indications Evaluation Process List
တၢ်ဃုသ့ၣ်ညါတၢ်အစၢ
တၢ်ပာ်ဖျါ 3411 - 3420 လၢ 4179 အစၢတဖၣ်အကျါ
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
Authorization Cancellation for Blue Cross (PDF)
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP81-25 Submitting Home Health Concurrent Reviews on Availity Essentials
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 24, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP80-25 Reminder: Criteria Used for Utilization Management (UM) Reviews
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 24, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP79-25 Update for New-to-Market Medical Drugs: zopapogene imadenovec
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 24, 2025
ကသံၣ်ကသီပှၤဟ့ၣ်မၤစၢၤတၢ်
QP62R1-25 Eyeglass Billing for Minnesota Health Care Programs Members
တၢ်ရဲၣ်တၢ်ကျဲၤစးထီၣ်မူ၀ဲ အမုၢ်နံၤမုၢ်သီ- လါစဲးပတ့ဘၢၣ် 24, 2025
2026 Small Group Network Adequacy Waiver - High Value Network
2026 Small Group Network Adequacy Waiver - High Value Network